Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor

Background: Melanoma is a heterogeneous malignancy that presents an immense challenge in therapeutic development. Recent approaches targeting the oncogenic MAP kinase pathways have shown tremendous improvement in the overall survival of patients with advanced melanoma. However, there is still an urg...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lili, Wang, Peiling, Sun, Yang, Liu, Sijing, Dai, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604444/
https://www.ncbi.nlm.nih.gov/pubmed/28928884
http://dx.doi.org/10.7150/jca.20319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604444/
https://www.ncbi.nlm.nih.gov/pubmed/28928884
http://dx.doi.org/10.7150/jca.20319

Ejemplares similares